Merck partnership accelerates needle-free vaccine delivery

October 9, 2012, University of Queensland

A University of Queensland invention that will deliver vaccines without the need for needles has struck a significant partnership with US-based pharmaceutical giant Merck, announced today.

The Nanopatch technology, which aims to replace the traditional needle and with a patch smaller than a postage stamp to deliver vaccines painlessly and more efficiently, will be licenced to Merck to begin commercial production on a vaccine.

UQ Vice-Chancellor Professor Peter Høj said the partnership accelerated the process of delivering the revolutionary health technology to people throughout the world.

"A major vaccine maker has looked at technologies around the world and chosen the UQ-invented Nanopatch," Professor Høj said.

"That is a tremendous credit to the team of researchers who developed the technology, led by Professor Mark Kendall.

"It also reflects the excellence of UQ's research , which ensures that practical, life-enhancing discoveries are made accessible to the people who need them.

"This link-up with Merck is especially inspiring, because it may lead to the relief of serious , particularly in remote and developing regions.

"In the immediate term, it will employ more people in Brisbane's innovation economy, and boost the global reputation of Queensland and Australian R&D."

The Nanopatch technology, now being developed by privately held biotechnology company Vaxxas, originated from Vaxxas Chief Technology Officer Professor Mark Kendall's research group at UQ's Australian Institute for Bioengineering and Nanotechnology.

"It is exciting to commence this important partnership between Vaxxas and Merck – a big step forward towards the Nanopatch becoming a vaccine delivery product," Professor Kendall said.

"This directly builds upon intensive and outstanding research on the Nanopatch – conducted by my research group at UQ – taking the Nanopatch from an idea to achieving unprecedented immune responses in animals. And our research has been supported by competitive research grants from both the Australian and Queensland State Governments."

Through the Merck partnership, Vaxxas will be eligible to receive payments for up to two additional vaccines developed by Merck using the Nanopatch platform, as well as milestone payments on Merck vaccine development and regulatory approvals, and royalties on sales of any vaccines that ultimately use the Nanopatch platform.

The Nanopatch works through thousands of small projections designed to deliver a to abundant immune cells in the skin, whereas the traditional syringe delivers to the muscle, where there are few immune cells.

Nanopatch delivery can improve the efficiency of vaccines—including achieving protection against influenza—with only 1/100th of the dose used with a needle and syringe.

The Nanopatch has the potential to improve patient convenience, reduce needle-stick injuries and overcome cross contamination.

It is designed for thermostability and may not need refrigeration, potentially making transport much cheaper and easier, particularly to developing nations.

Related Stories

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.